http://ift.tt/eA8V8J
Massachusetts-based Concert Pharmaceuticals Inc. has received a second request for information from the U.S. Federal Trade Commission for the planned sale of its investigational cystic fibrosis treatment to Vertex Pharmaceuticals Inc. in a deal worth up to $250 million, the company said Monday.
May 23, 2017 at 03:36AM
from
No comments:
Post a Comment